Slide 1: Addressing Unmet Needs in Acute GvHD: KOL insights and MaaT013 Data from ASH
g os Sa MaaT Pharma > Addressing Unmet Needs in Acute GvHD: KOL insights a MaaT013 Data fromthe G6 3% ASH Annual Meeting
Slide 2: Disclaimer
4a ASH 2024 Disclaimer This document has been prepared by Maa Pharma (the “Company*) andis for informationandbackgroundpurposesonly. While the information contained herein has been preparedin good faith, neither the Company, nor its shareholders, directors, officers, agents, employees, or advisors g
Slide 3: Speakers on Today's Call
ASH 2024 Speakers on Today’s Call Pr. Mohamad Mohty, M.D! Professor, Sorbonne University and Head of the Clinical Hematology and Cellular Department, Saint-Antoine Hospital (AP-HP), Paris, France ASSISTANCE HOPITAUX DE PARIS PUBLIQUE Monzr M. Al Malki M.D. Associate Professor and Director of Unrelat
Slide 4: Agenda
ASH 2024 Dec 2024 4 oel¥ or s Agenda i Introduction - Herve Affagard Unmet Need for MaaT013 in GvHD in Europe and the US — Prof. Mohty & Dr. Al Malki MaaT1013: Results from the Early Access Program in Europe - Prof. Mohty Next steps for MaaT013 —- Hervé Affagard Q&A OOOO
Slide 5: Success in Refractory GVHD Will Pave the Way for Broad Therapeutic Advances
4a ASH 2024 Success in Refractory GVHD Will Pave the Way for Broad Therapeutic Advances with Exceptional Potential for MaaT Pharma Breakthrough advances of MaaT013 in GVHD ©) Recruitment completed for Phase 3 in aGvHD in Europe, expecting primary endpoint readout in January 2025 Positive data from E
Slide 6: A Strong Pipeline With Multiple Near-Term Value Inflection Milestones
MaaT Pharma November 2024 6 A Strong Pipeline With Multiple Near-Term Value Inflection Milestones x Program Indication Market potential Preclinical Phase] Phase 2 Phase 3 Status BUpcoming milestone ~250mM€ Fully ; > , Fe) MaaTO13 aGvHD IL: 10k patients? i ~~ recruited ChORR January 2028 ODD EMA/FDA
Slide 7: Richness (OTUs)
es D Unpaired t-test with Welch's correction ° 800 <0.0001 Richness (OTUs) 600 ✓ 400 ches ✓ 200 0 Single Pools donors MaaT013 batches
Slide 8: Since 2019: a positive trend in EAP showing clinical adoption
4a ASH 2024 Since 2019: a positive trend in EAP showing clinical adoption Patients Increase requests from physicians around the 150 world especially in Europe & 1st US patient treated under SPU at City of Hope SOW BOS »>OOS Increase revenues for MaaT013 (year-on-year) -> 100 50 2.3mé€ for the nine f
Slide 9: Unmet Need for MaaT013 in GVHD in Europe and in the US
at ws wo” Sy @ | & al a Unmet Need for oe MaaT013 in GVHD in Pi i , ¢ Europe and in the US * * i, 5 @ aS Swe = &
Slide 10: aGvHD, a life-threatening complication following Allo-HSCT
4 > ASH 2024 Dec 2024 10 AGvHD, a life-threatening complication following Allo-HSCT — It may occur in 50% of patients undergoing allogeneic hematopoietic stem cell transplantation (Allo-HSCT), typically presenting within the first 100 days post-transplant SN Common clinical manifestations typically
Slide 11: Current Challenges in GVHD Management
4a ASH 2024 Current Challenges in GVHD Management High Morbidity and Mortality * Chronic GvHD impacts long-term quality of life and organ function. + Acute GvHD, especially steroid-refractory forms, is associated with high mortality rates. aGvHD approved drugs in adult population High-dose corticost
Slide 12: No approved therapies in 3L treatment
ASH 2024 No approved therapies in 3L treatment PAA 80%. of eeu = Around 3,000 per year Limited Efficacy of Current Options High Toxicity Profiles Need for Novel Treatments & 85% lyear mortality in 3L+! Survival rate 0.50 0.00 180 ‘Abedin Dec 2024 tal, Br
Slide 13: Urgent medical need in 3L treatment
a ASH 2024 Urgent medical need in 3L treatment aGvHD drugs in development - as of December 2024 IL- in combination with corticosteroids 2L 3L- grade I-IV SR Gl-aGvHD *Ongoing, active a going, Primary Dec 2024 13 WT completion End of Study Itolizumab - Phase III >) 12/2024* 12/2025 B) alpha-l protein
Slide 14: Higher Gut Microbiome Diversity is Associated with Increased Survival
ASH 2024 In Allo-HSCT, a Higher Gut Microbiome Diversity is Associated with Increased Survival Lower incidence and lower mortality rate from aGvHD2 Cumulative incidence (%) Inverse Simpson diversity index 70, 2d GVHD-related mortality 60 ao -- Lower diversity (n=32 = Higher diversity (n=32) 40: 30:
Slide 15: MaaT013, mechanism of action with restoration of homeostasis
ASH 2024 15 MaaTO013, mechanism of action with restoration of homeostasis High Diversity Cytotoxic Butycore® conditioning regimen Loss of microbial diversity & gut barrier integrity Anti-inflammatory _metabolites Bacterial Tiger 2 translocation r < damage : Bile acids an indoles “ T PAMPs , DAMPs H
Slide 16: MaaT013: Results from the Early Access Program in Europe
MaaT013: Results from the Early Access Program in Europe
Slide 17: Early Access Program (EAP): giving access to MaaT013 for patients with no options
ASH 2024 Early Access Program (EAP): giving access to MaaT013 for patients with no options + InFrance: Authorized by the French regulator (ANSM) with Governing protocol for use * Inother countries in Europe: compassionate use Data from 154 patients treated from July 2018 to April 2024, in 27 Europea
Slide 18: Probability of Survival
Responders 100 Non responders All patients Probability of Survival 50 0 0 180 360 540 720 Time (days)
Slide 19: Probability of Survival
Responders 100 Non respondersResponders 100 All patients Non responders Probability of Survival All patients Probability of Survival 50 50 0 0 0 180 360 540 720 0 180 360 540 (days) Time 720 Time (days)
Slide 20: Conclusions
4a ASH 2024 Dec 2024 20 Conclusions MaaT0i3 is highly effective therapy for SR- and SD-GI- aGvHD * D28 GI-ORR 51% and ORR 49% * Excellent responses in the ruxolitinib-refractory patients (MaaT013 as 3rd line), with high rates of CR and VGPR at D28, maintained at D56 * D28 GI-ORR 59% and ORR 55% * D5
Slide 21: ARES, a Pivotal Phase 3 Trial to Treat aGvHD in 3L
2i ARES, a Pivotal Phase 3 Trial to Treat aGvHD in 3L with Topline Expected ‘ ° in January 2025 ARES + jy Treatment Period DI, 5, 10 66 Patients with SR-Gl-aGvHD (Europe) ? mo Dy us MaaTO013 administration 4th dose if relapse after response Inclusion crite vous DI p28 Mé m2 | Refractory or intoleran
Slide 22: Near-Term Value Inflection Milestones for MaaT013
MaaT Pharma, November 2024 22 Near-Term Value Inflection Milestones for MaaT013 x >) GvHD | EAP Update ASH24 4 January: GVHD | ARES P3 GLORR GVHD | ARES Final Results (OS) Marketing authorizationin Europe anticipated Q1: IO Mela. | PICASSO P2a Results GvHD | Filing to EMA Vv Potential first Microbio
Slide 23: Q&A session
Q&A session
Slide 24: Speakers on Today's Call
ASH 2024 Speakers on Today’s Call Pr. Mohamad Mohty, M.D! Professor, Sorbonne University and Head of the Clinical Hematology and Cellular Department, Saint-Antoine Hospital (AP-HP), Paris, France ASSISTANCE HOPITAUX DE PARIS PUBLIQUE Monzr M. Al Malki M.D. Associate Professor and Director of Unrelat
Slide 25: Thank you
Thank you